Differential Expression and miRNA–Gene Interactions in Early and Late Mild Cognitive Impairment
Abstract
:1. Introduction
2. Materials and Methods
2.1. Gene Expression Data
2.2. MicroRNA Expression Data
2.3. Differential Expression Analysis of Gene and miRNA
3. Results
3.1. Differential Expression in EMCI and LMCI Gene Profile
3.2. Differential Expression on miRNome and miRNA–Gene Interactions
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
Abbreviations
AD | Alzheimer’s Disease |
EMCI | Early Mild Cognitive Impairment |
LMCI | Late Mild Cognitive Impairment |
MMSE | Mini-Mental State Exam |
References
- Bertram, L. Alzheimer’s disease genetics current status and future perspectives. Int. Rev. Neurobiol. 2009, 84, 167–184. [Google Scholar] [PubMed]
- Baum, L.; Chen, L.; Ng, H.K.; Pang, C.P. Apolipoprotein E isoforms in Alzheimer’s disease pathology and etiology. Microsc. Res. Techn. 2000, 50, 278–281. [Google Scholar] [CrossRef]
- Kamboh, M.I. Molecular genetics of late-onset Alzheimer’s disease. Ann. Hum. Genet. 2004, 68, 381–404. [Google Scholar] [CrossRef] [PubMed]
- Rabinovici, G.D. Late-onset Alzheimer disease. Cont. Lifelong Learn. Neurol. 2019, 25, 14–33. [Google Scholar] [CrossRef]
- Gauthier, S.; Reisberg, B.; Zaudig, M.; Petersen, R.C.; Ritchie, K.; Broich, K.; Belleville, S.; Brodaty, H.; Bennett, D.; Chertkow, H.; et al. Mild cognitive impairment. Lancet 2006, 367, 1262–1270. [Google Scholar] [CrossRef]
- Aisen, P.S.; Petersen, R.C.; Donohue, M.C.; Gamst, A.; Raman, R.; Thomas, R.G.; Walter, S.; Trojanowski, J.Q.; Shaw, L.M.; Beckett, L.A.; et al. Clinical Core of the Alzheimer’s Disease Neuroimaging Initiative: Progress and plans. Alzheimers Dement 2010, 6, 239–246. [Google Scholar] [CrossRef] [Green Version]
- Petersen, R.C. Alzheimer’s disease: Progress in prediction. Lancet Neurol. 2010, 9, 4–5. [Google Scholar] [CrossRef] [Green Version]
- Cherbuin, N.; Leach, L.S.; Christensen, H.; Anstey, K.J. Neuroimaging and APOE genotype: A systematic qualitative review. Demen. Geriatr. Cognit. Disord. 2007, 24, 348–362. [Google Scholar] [CrossRef]
- Berchtold, N.C.; Sabbagh, M.N.; Beach, T.G.; Kim, R.C.; Cribbs, D.H.; Cotman, C.W. Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer’s disease. Neurobiol. Aging 2014, 35, 1961–1972. [Google Scholar] [CrossRef] [Green Version]
- Cacabelos, R.; Torrellas, C. Epigenetics of aging and Alzheimer’s disease: Implications for pharmacogenomics and drug response. Int. J. Mol. Sci. 2015, 16, 30483–30543. [Google Scholar] [CrossRef] [Green Version]
- Hammond, S.M. An overview of microRNAs. Adv. Drug Deliv. Rev. 2015, 87, 3–14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Leidinger, P.; Backes, C.; Deutscher, S.; Schmitt, K.; Mueller, S.C.; Frese, K.; Haas, J.; Ruprecht, K.; Paul, F.; Stähler, C.; et al. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 2013, 14, R78. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aisen, P.S.; Petersen, R.C.; Donohue, M.; Weiner, M.W.; Alzheimer’s Disease Neuroimaging Initiative. Alzheimer’s Disease Neuroimaging Initiative 2 clinical core: Progress and plans. Alzheimer’s Dement. 2015, 11, 734–739. [Google Scholar] [CrossRef] [Green Version]
- The GTEx Consortium. The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. Science 2015, 348, 648–660. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shen, E.H.; Overly, C.C.; Jones, A.R. The Allen Human Brain Atlas: Comprehensive gene expression mapping of the human brain. Trends Neurosci. 2012, 35, 711–714. [Google Scholar] [CrossRef]
- Smyth, G.K. Limma: Linear models for microarray data. In Bioinformatics and Computational Biology Solutions Using R and Bioconductor; Springer: Berlin, Germany, 2005; pp. 397–420. [Google Scholar]
- Robinson, M.D.; McCarthy, D.J.; Smyth, G.K. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010, 26, 139–140. [Google Scholar] [CrossRef] [Green Version]
- Wickham, H.; Chang, W. ggplot2: An implementation of the Grammar of Graphics. R Package Version 0.7. 2008. Available online: http://CRAN.R-project.org/package=ggplot2 (accessed on 10 January 2020).
- Gu, Z.; Eils, R.; Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 2016, 32, 2847–2849. [Google Scholar] [CrossRef] [Green Version]
- Hsu, S.D.; Lin, F.M.; Wu, W.Y.; Liang, C.; Huang, W.C.; Chan, W.L.; Tsai, W.T.; Chen, G.Z.; Lee, C.J.; Chiu, C.M.; et al. miRTarBase: A database curates experimentally validated microRNA–target interactions. Nucleic Acids Res. 2010, 39, D163–D169. [Google Scholar] [CrossRef] [Green Version]
- Burgos, K.; Malenica, I.; Metpally, R.; Courtright, A.; Rakela, B.; Beach, T.; Shill, H.; Adler, C.; Sabbagh, M.; Villa, S.; et al. Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer’s and Parkinson’s diseases correlate with disease status and features of pathology. PLoS ONE 2014, 9, e94839. [Google Scholar] [CrossRef]
- Nagaraj, S.; Laskowska-Kaszub, K.; Dębski, K.J.; Wojsiat, J.; Dąbrowski, M.; Gabryelewicz, T.; Kuźnicki, J.; Wojda, U. Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer’s disease patients from non-demented subjects. Oncotarget 2017, 8, 16122. [Google Scholar] [CrossRef] [Green Version]
- Tan, L.; Yu, J.T.; Tan, M.S.; Liu, Q.Y.; Wang, H.F.; Zhang, W.; Jiang, T.; Tan, L. Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer’s disease. J. Alzheimer’s Dis. 2014, 40, 1017–1027. [Google Scholar] [CrossRef] [PubMed]
- Satoh, J.I.; Kino, Y.; Niida, S. MicroRNA-Seq data analysis pipeline to identify blood biomarkers for Alzheimer’s disease from public data. Biomark. Insights 2015, 10, BMI-S25132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sørensen, S.S.; Nygaard, A.B.; Christensen, T. miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer’s disease and other types of dementia—An exploratory study. Transl. Neurodegener. 2016, 5, 6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hara, N.; Kikuchi, M.; Miyashita, A.; Hatsuta, H.; Saito, Y.; Kasuga, K.; Murayama, S.; Ikeuchi, T.; Kuwano, R. Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer’s disease. Acta Neuropathol. Commun. 2017, 5, 10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Du Yan, S.; Chen, X.; Fu, J.; Chen, M.; Zhu, H.; Roher, A.; Slattery, T.; Zhao, L.; Nagashima, M.; Morser, J.; et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer’s disease. Nature 1996, 382, 685–691. [Google Scholar] [CrossRef]
- Cai, Z.; Liu, N.; Wang, C.; Qin, B.; Zhou, Y.; Xiao, M.; Chang, L.; Yan, L.J.; Zhao, B. Role of RAGE in Alzheimer’s disease. Cell. Mol. Neurobiol. 2016, 36, 483–495. [Google Scholar] [CrossRef]
- Lo, R.Y. The borderland between normal aging and dementia. Tzu-Chi Med. J. 2017, 29, 65. [Google Scholar]
- Wang, C.; Lv, X.; He, C.; Hua, G.; Tsai, M.; Davis, J.S. The G-protein-coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian cancer cells by blocking tubulin polymerization. Cell Death Dis. 2013, 4, e869. [Google Scholar] [CrossRef] [Green Version]
- Rempe, R.G.; Hartz, A.M.; Bauer, B. Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers. J. Cereb. Blood Flow Metab. 2016, 36, 1481–1507. [Google Scholar] [CrossRef] [Green Version]
- Tanskanen, M.; Myllykangas, L.; Saarialho-Kere, U.; Paetau, A. Matrix metalloproteinase–19 expressed in cerebral amyloid angiopathy. Amyloid 2011, 18, 3–9. [Google Scholar] [CrossRef]
- Belrose, J.C.; Jackson, M.F. TRPM2: A candidate therapeutic target for treating neurological diseases. Acta Pharmacol. Sin. 2018. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Weiss, N.; Koschak, A. Pathologies of Calcium Channels; Springer: Berlin/Heidelberg, Germany, 2013. [Google Scholar]
- Ransohoff, J.D.; Wei, Y.; Khavari, P.A. The functions and unique features of long intergenic non-coding RNA. Nat. Rev. Mol. Cell Biol. 2018, 19, 143. [Google Scholar] [CrossRef] [PubMed]
- Gui, Y.; Liu, H.; Zhang, L.; Lv, W.; Hu, X. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget 2015, 6, 37043. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, P.; Huang, R.; Lu, S.; Xia, W.; Cai, R.; Sun, H.; Wang, S. RAGE and AGEs in mild cognitive impairment of diabetic patients: A cross-sectional study. PLoS ONE 2016, 11, e0145521. [Google Scholar] [CrossRef] [Green Version]
- Brkic, M.; Balusu, S.; Libert, C.; Vandenbroucke, R.E. Friends or foes: Matrix metalloproteinases and their multifaceted roles in neurodegenerative diseases. Med. Inflamm. 2015, 2015. [Google Scholar] [CrossRef] [Green Version]
- Stojic, J.; Hagemann, C.; Haas, S.; Herbold, C.; Kühnel, S.; Gerngras, S.; Roggendorf, W.; Roosen, K.; Vince, G.H. Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. Neurosci. Res. 2008, 60, 40–49. [Google Scholar] [CrossRef]
- Bruno, M.A.; Mufson, E.J.; Wuu, J.; Cuello, A.C. Increased matrix metalloproteinase 9 activity in mild cognitive impairment. J. Neuropathol. Exp. Neurol. 2009, 68, 1309–1318. [Google Scholar] [CrossRef]
- Van Horssen, J.; Vos, C.; Admiraal, L.; Van Haastert, E.; Montagne, L.; Van der Valk, P.; De Vries, H. Matrix metalloproteinase-19 is highly expressed in active multiple sclerosis lesions. Neuropathol. Appl. Neurobiol. 2006, 32, 585–593. [Google Scholar] [CrossRef]
- Okello, A.; Edison, P.; Archer, H.; Turkheimer, F.; Kennedy, J.; Bullock, R.; Walker, Z.; Kennedy, A.; Fox, N.; Rossor, M.; et al. Microglial activation and amyloid deposition in mild cognitive impairment: A PET study. Neurology 2009, 72, 56–62. [Google Scholar] [CrossRef] [Green Version]
- Kurt, A.H.; Yuksel, K.Z.; Uremis, N.; Uremis, M.M.; Altun, I.; Bosnak, M.; Kilicaslan, D.; Alli, B. Protective Effects of G Protein-Coupled Estrogen Receptor 1 (GPER1) on β-Amyloid-Induced Neurotoxicity: Implications for Alzheimer’s Disease. Neurochem. J. 2019, 13, 99–104. [Google Scholar] [CrossRef]
- Wang, L.L.; Min, L.; Guo, Q.D.; Zhang, J.X.; Jiang, H.L.; Shao, S.; Xing, J.G.; Yin, L.L.; Liu, J.H.; Liu, R.; et al. Profiling microRNA from brain by microarray in a transgenic mouse model of Alzheimer’s disease. BioMed Res. Int. 2017, 2017. [Google Scholar] [CrossRef] [PubMed]
- Ye, Z.; Sun, B.; Mi, X.; Xiao, Z. Gene co-expression network for analysis of plasma exosomal miRNAs in the elderly as markers of aging and cognitive decline. PeerJ 2020, 8, e8318. [Google Scholar] [PubMed]
- Hooten, N.N.; Fitzpatrick, M.; Wood, W.H., III; De, S.; Ejiogu, N.; Zhang, Y.; Mattison, J.A.; Becker, K.G.; Zonderman, A.B.; Evans, M.K. Age-related changes in microRNA levels in serum. Aging 2013, 5, 725. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- He, R.; Xie, X.; Lv, L.; Huang, Y.; Xia, X.; Chen, X.; Zhang, L. Comprehensive investigation of aberrant microRNAs expression in cells culture model of MnCl2-induced neurodegenerative disease. Biochem. Biophys. Res. Commun. 2017, 486, 342–348. [Google Scholar] [CrossRef] [PubMed]
- Calne, D.; Chu, N.; Huang, C.; Lu, C.; Olanow, W. Manganism and idiopathic parkinsonism: Similarities and differences. Neurology 1994, 44, 1583–1586. [Google Scholar] [CrossRef]
- Hu, Y.B.; Li, C.B.; Song, N.; Zou, Y.; Chen, S.D.; Ren, R.J.; Wang, G. Diagnostic value of microRNA for Alzheimer’s disease: A systematic review and meta-analysis. Front. Aging Neurosci. 2016, 8, 13. [Google Scholar] [CrossRef] [Green Version]
- Hébert, S.S.; Papadopoulou, A.S.; Smith, P.; Galas, M.C.; Planel, E.; Silahtaroglu, A.N.; Sergeant, N.; Buée, L.; De Strooper, B. Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum. Mol. Genet. 2010, 19, 3959–3969. [Google Scholar] [CrossRef] [Green Version]
- Absalon, S.; Kochanek, D.M.; Raghavan, V.; Krichevsky, A.M. MiR-26b, upregulated in Alzheimer’s disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J. Neurosci. 2013, 33, 14645–14659. [Google Scholar] [CrossRef]
- Whyte, L.S.; Lau, A.A.; Hemsley, K.M.; Hopwood, J.J.; Sargeant, T.J. Endo-lysosomal and autophagic dysfunction: A driving factor in Alzheimer’s disease? J. Neurochem. 2017, 140, 703–717. [Google Scholar] [CrossRef] [Green Version]
- Peng, M.; Wang, J.; Zhang, D.; Jin, H.; Li, J.; Wu, X.R.; Huang, C. PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein. Oncogene 2018, 37, 5735–5748. [Google Scholar] [CrossRef] [Green Version]
Probe Expression Level | ||||||
---|---|---|---|---|---|---|
Gene | Chr | Region | LogFC | AveExpr | p-Value | FDR (p-Value) |
AGER (11762194_x_at) | 6 | 6p21.32 | 0.16 | 4.86 | 3.38 × 10 | 0.016 |
LINC00482 (11735339_at) | 17 | 17q25.3 | 0.14 | 3.80 | 1.35 × 10 | 0.033 |
AGER (11745620_x_at) | 6 | 6p21.32 | 0.19 | 5.80 | 3.68 × 10 | 0.041 |
MMP19 (11751287_a_at) | 12 | 12q13.2 | 0.09 | 2.44 | 3.89 × 10 | 0.041 |
CATSPER1 (11731807_at) | 11 | 11q13.1 | 0.18 | 6.31 | 4.16 × 10 | 0.041 |
Mean of Probe Expression Level | ||||||
Gene | Chr | Region | LogFC | AveExpr | p-value | FDR (p-value) |
PHLPP2 | 16 | 16q22.2 | −0.1184 | 3.60 | 4.62 × 10 | 0.009 |
LINC00482 | 17 | 17q25.3 | 0.0851 | 3.05 | 2.39 × 10 | 0.018 |
TRPM2 | 21 | 21q22.3 | 0.0740 | 3.33 | 2.70 × 10 | 0.018 |
CATSPER1 | 11 | 11q13.1 | 0.1888 | 6.31 | 4.14 × 10 | 0.020 |
GPER1 | 7 | 7p22.3 | 0.0911 | 3.68 | 6.74 × 10 | 0.027 |
AGER | 6 | 6p21.32 | 0.1478 | 5.76 | 1.13 × 10 | 0.037 |
ARFGAP1 | 20 | 20q13.33 | 0.0855 | 4.79 | 1.70 × 10 | 0.048 |
miRNA | logFC | FDR (p-Value) | Experiment | Target Gene | References |
---|---|---|---|---|---|
hsa-miR-10a-5p | −0.699380073 | 5.8 × 10 | CLASH | AGER | [21] |
hsa-miR-151a-5p | −0.345619322 | 3.4 × 10 | HITS-CLIP | GPER1 | [22] |
hsa-miR-151b | −0.345583534 | 3.4 × 10 | HITS-CLIP | GPER1 | [23] |
hsa-miR-15a-5p | 1.292271145 | 3.9 × 10 | PAR-CLIP | PHLPP2 | [24,25] |
hsa-miR-26b-5p | 0.692598872 | 2.1 × 10 | Microarray | PHLPP2 | [12,26] |
hsa-miR-26b-5p | 0.692598872 | 2.1 × 10 | Microarray | LINC00483 | [12,26] |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Brito, L.M.; Ribeiro-dos-Santos, Â.; Vidal, A.F.; de Araújo, G.S., on behalf of the Alzheimer’s Disease Neuroimaging Initiative. Differential Expression and miRNA–Gene Interactions in Early and Late Mild Cognitive Impairment. Biology 2020, 9, 251. https://doi.org/10.3390/biology9090251
Brito LM, Ribeiro-dos-Santos Â, Vidal AF, de Araújo GS on behalf of the Alzheimer’s Disease Neuroimaging Initiative. Differential Expression and miRNA–Gene Interactions in Early and Late Mild Cognitive Impairment. Biology. 2020; 9(9):251. https://doi.org/10.3390/biology9090251
Chicago/Turabian StyleBrito, Leonardo Miranda, Ândrea Ribeiro-dos-Santos, Amanda Ferreira Vidal, and Gilderlanio Santana de Araújo on behalf of the Alzheimer’s Disease Neuroimaging Initiative. 2020. "Differential Expression and miRNA–Gene Interactions in Early and Late Mild Cognitive Impairment" Biology 9, no. 9: 251. https://doi.org/10.3390/biology9090251